RxDoctor Payments Data

Melodye Campbell, APRN

Family · Bowling Green, KYNPI 1780054452

Payments from drug & device makers

$4,170in general payments, 2019–2025

Across 273 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$679
  • Pfizer$616
  • Lilly USA, LLC$357
  • AbbVie$304
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$264
  • Boehringer Ingelheim$211
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,170 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$173,181
Medicare patients
550
Services billed
8,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$101,643
FarxigaDapagliflozin Propanediol42$44,526
TrulicityDulaglutide25$39,071
OzempicSemaglutide37$38,758
MounjaroTirzepatide24$30,924
JanuviaSitagliptin Phosphate23$26,537
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$22,530
JardianceEmpagliflozin20$22,050
MyrbetriqMirabegron17$14,660
XareltoRivaroxaban14$11,031
Tresiba Flextouch U-200Insulin Degludec12$9,188
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$7,168
Levothyroxine Sodium375$4,505
Albuterol Sulfate HfaAlbuterol Sulfate132$3,772
Atorvastatin Calcium585$3,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$616$101,643107 claims
Lilly USA, LLCTrulicity, Mounjaro$357$69,99549 claims
AstraZenecaFarxiga, Symbicort$38$47,56254 claims
Novo NordiskOzempic$679$38,75837 claims
GSKTrelegy Ellipta$184$22,53023 claims
Boehringer IngelheimJardiance$211$22,05020 claims
Astellas Pharma US IncMyrbetriq$106$14,66017 claims
Johnson & JohnsonXarelto$18$11,03114 claims
AbbVieSynthroid$304$1,32842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →